. The usual clinical dosage of 10-40 mg/day of rosuvastatin has been shown to achieve a 46-55% reduction in LDL-C [5] . Recently, the introduction of generic statins has enabled highly cost-effective LDL-C reduction in clinical practice and third party payers often recommend substitution of branded agents with generic alternatives [6] . However, even if switching from brand-name drugs to generic equivalents may reduce prescription costs, it may also potentially compromise therapeutic benefits if generic options are not of equivalent efficacy [7] . In fact, switching from a particular statin to another non-equipotent lipid lowering treatment may alter lipid control by causing a significant LDL-C increase [7, 8] . In line with this observation, switching from more effective to less effective lipid lowering agents has been associated with a higher probability of negative clinical outcomes in high risk clinical conditions [8, 9] .
The aim of this study was to assess the clinical impact of switching from rosuvastatin treatment to any other lipid lowering therapy on clinical outcomes in the Italian general practice setting.
METHODS
The analysis in this article was based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.
Data Source
This was a retrospective analysis based on data extracted from the IMS Agency recommends the prescription of high-dose atorvastatin in patients with previous major adverse cardiovascular events, other exclusion criteria were the history of a prior AMI, of a prior stroke, and of any prior revascularization procedure [13] . Besides, ''sporadic'' patients, i.e., patients with only one prescription of any statin over the entire period of observation, as well as patients treated with low-dose rosuvastatin (i.e., 5 mg/day) were also excluded from the analysis.
Primary End Point
The primary end point of the study was the occurrence of an AMI during the observation period.
Patients were considered to have experienced an AMI (ICD-9-CM code 410) when such an event was recorded in the IMS Health LPD. This specific end point was chosen as it is clinically relevant, easily ascertainable from clinical records and hospital discharge documents [14] , and potentially sensitive to more intensive lipid lowering therapy [3, 15] .
Besides, a ''universal definition'' for AMI is currently available, which has also been endorsed by all Italian scientific and professional associations [16] . Other major cardiovascular events do not share the same degree of reliability in terms of clinical diagnosis and coding in primary care and could be underreported [17] .
Statistical Analysis
Means (±standard deviation) were calculated for continuous variables, while frequencies were measured for categorical variables. covariate. This approach has already been employed in similar previous studies [8, 18] because patients can be moved from one risk class to another at the moment of documented modification of pharmacological treatment. 
RESULTS
The final study population included 10,368 new patients that started on ''high-intensity statin treatment'' [19] with rosuvastatin (10-40 mg/day) in the period between January 2011 and December 2013 according to the inclusion criteria.
During the entire period of observation, 2452 (23.6%) patients were switched from rosuvastatin to another lipid lowering treatment. Most of the patients were switched to atorvastatin (55.6%), followed by simvastatin (24.9%), simvastatin/ezetimibe (10.0%) combination and other statins (9.5%). Besides, in the vast majority of cases this therapeutic substitution could be considered as non-equipotent in terms of LDL-C reduction and according to current definitions [19] , most patients (1777; 72.4%) were switched to ''medium'' or ''low intensity'' statin treatment (10-20 mg/day of atorvastatin in 1042 patients; 42.5%; 10-20 mg/day of simvastatin in 502 patients; 20.4%; other low-potency statin agents, such as pravastatin and lovastatin in 233 patients; 9.5%).
Demographic and clinical characteristics of the study population at baseline are reported in Authorities have promoted specific policies in favor of switching from branded statins to generic alternatives during the study period (2011-2015) [13, 24] . It seems highly probable that these cost-cutting policies may have had a role in encouraging GPs to switch from rosuvastatin to other pharmacological agents, even in the absence of any significant clinical issue. Another point of major interest emerging from this study is that switching from rosuvastatin treatment to other lipid lowering therapies was associated with a twofold higher probability of AMI during the observation period. Such relevant increase in cardiovascular risk was independent from all major demographic and clinical features. This result is consistent with previously reported observations supporting the notion that switching from more effective to less effective lipid lowering interventions may impart a higher probability of negative clinical outcomes in high risk clinical conditions [8] .
Moreover, this evidence is also coherent with data from specific computer simulated clinical trials on rosuvastatin [9] . Overall, clinical studies have clearly shown that both LDL-C levels and cardiovascular outcomes are directly related to statin potency and dosing [2, 3] . In this study, most patients experienced a non-equipotent switch to less effective doses of less potent agents, clearly moving from ''high'' to ''medium'' or even ''low'' intensity statin therapy [19] . 
